Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Overview of Key Overnight Developments on May 21

Overview of Key Overnight Developments on May 21

金色财经金色财经2025/05/20 23:40
Show original

21:00-7:00 Keywords: Gold, Blackstone, Uniswap, Texas

1. Michael Saylor: Bitcoin is transforming the equity capital markets;

2. Bitcoin open interest reaches an all-time high of $72 billion;

3. Blackstone makes its first bet on Bitcoin, purchasing only $1.08 million in IBIT funds;

4. Bancor sues Uniswap for infringing on its DEX smart contract technology patent;

5. Gold returns to $3,300, reportedly as Israel prepares to strike Iranian nuclear facilities;

6. Texas passes Bitcoin reserve investment bill, awaiting governor's approval to take effect;

7. US SEC Chairman: Promoting transparency and accountability in SEC's crypto regulation;

8. US SEC delays decision on XRP and Dogecoin ETF proposals, seeking public comment.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

US Stock Movement | US clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) enters the US stock market, shares drop over 10% after opening

According to Jinse Finance, Retension Pharmaceuticals (RTSN.US) debuted on the US stock market on Friday and fell over 10% to $10.77 at press time, with an IPO price of $12. Retension Pharmaceuticals is a US-based clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of hypertension and other cardiovascular diseases. The company's core investigational drug, RTN-001, is a new generation phosphodiesterase 5 (PDE5) inhibitor, primarily targeting patients with uncontrolled or resistant hypertension, and is currently undergoing a Phase IIb clinical trial. This drug works by enhancing nitric oxide signaling in blood vessels to promote vasodilation and lower blood pressure. The exclusive global development license comes from French pharmaceutical giant Sanofi (SNY.US).

智通财经•2026/10/09 16:36

Chevron has suspended production operations at five facilities in the U.S. Gulf region.

Chevron (CVX.US) has evacuated personnel and shut down production operations at five facilities in the US Gulf region, while another four offshore platforms continue production.

智通财经•2026/10/09 16:31